Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)

Secondary care notes

• NMUH approval:
  
  • Not applicable
• RFL approval:
  
  • Not applicable
• RNOH approval:
  
  •  Requires Haematologist approval. See restriction above.
• UCLH approval:
  
  •  Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
• WH approval:
  
  • Not applicable

Secondary care notes

• NMUH approvals:
  
  • See links below
• RFL approvals:
  
  • See links below
• RNOH approvals:
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • Nil

Secondary care notes

• NMUH approvals:
  
  • See links below
• RFL approvals:
• RNOH approvals:
  • Not applicable
• UCLH approvals:
• WH approvals:
  • Not applicable

Secondary care notes

• NMUH approvals:
  
  • Not applicable
• RFL approvals:
  
  • For the treatment of acute coronary syndrome only Low molecular weight heparin protocol
• RNOH approvals
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • Not applicable

Not approved for anticoagulation in renal failure/obesity (JFC March 2013)

Secondary care notes

• NMUH approvals:
  
  • Tinzaparin is FORMULARY when used for the treatment of suspected/confirmed DVT/PE & for Thromboprophylaxis.
  • See links below
• RFL approvals:
  
  • See links below
• RNOH approvals
  
  • Not applicable
• UCLH approvals:
• WH approvals:
  
  • Nil

Secondary care notes

• NMUH approvals:
  
  • Not Applicable
• RFL approvals:
  
  • See links below
• RNOH approvals
  
  • Not Applicable
• UCLH approvals:
• WH approvals:
  
  • Not Applicable

Secondary care notes

• NMUH approvals:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
• RFL approvals:
  
  • Restricted to use in the Cardiology Cath Lab only.
• RNOH approvals:
  
  •  Restricted
• UCLH approvals:
• WH approvals:
  
  • NICE TA230 applies. Not routinely stocked at WH.

 Secondary care notes

• NMUH approvals:
  
  • Nil
• RFL approvals:
  • Nil
• RNOH approvals:
• UCLH approvals:
• WH approvals:
  • Nil

Approved for pulmonary hypertension (November 2013)

Secondary care notes

• NMUH approvals
  
  • Restricted for ICU use only.
  • Check MHRA for Drug Safety Updates
• RFL approvals:
  
  • Restricted to ITU and pulmonary hypertension
• RNOH approvals:
  
  • Not applicable
• UCLH approvals:
  
  • Approved for primary pulmonary hypertension: functional grades III + IV
  • Approved for Inhibition of platelet aggregation during renal dialysis
• WH approvals:
  
  • Nil

Secondary care notes

• NMUH approvals:
  
  • Restricted to use for patients with Unstable Angina / NSTEMI.
  • See Trust Guideline on use
• RFL approvals:
  
  • Restricted - only to be used under the advice of the haemophilia consultant
• RNOH approvals
  
  • Nil
• UCLH approvals:
• WH approvals:
  
  • Restricted for use in unstable angina and NSTMEI